Submissions from 2024
Real-world outcomes in patients with biomarker-selected early-stage non-small cell lung cancer, Fawzi Abu Rous, Jesse Sussell, Celina Ngiam, Qing Zhang, Thomas Majda, Daniel Sheinson, Sarika Ogale, Ilze Bara, Katja Schulze, and Shirish M. Gadgeel
PP01.107 Patient Characteristics and Treatment Patterns in Biomarker Selected Early Non-Small Cell Lung Cancer, Fawzi Abu Rous, Jesse Sussell, Celina Ngiam Kochounian, Qing Zhang, Thomas Majda, Danny Sheinson, Sarika Ogale, Ilze Bara, and Shirish Gadgeel
Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial, Joachim Aerts, Luis G. Paz-Ares, Carole Helissey, Federico Cappuzzo, Gilles Quere, Dariusz Kowalski, Jose Carlos Benitez Sr., Florian Guisier, Benjamin Besse, Shirish M. Gadgeel, Thomas Wehler, Ignacio Gil-Bazo, Michael Jon Chisamore, Cem Gorgun, Ilhan Celik, Marie Holst Mørch, Patricia Garrido Castro, Teng Jin Ong, and Enriqueta Felip
A comprehensive analysis of the molecular landscape of HER3 expression in adenocarcinoma of the lung, S. K. Alhushki, A. N. Al-Bzour, N. N. Al-Bzour, H. M. Abushukair, and Fawzi Abu Rous
PP01.114 Outcomes of Patients Diagnosed with Lung Cancer after COVID-19 Infection, Zaid Al-Saheli, Omar Ammari, Linda Albusoul, Fawzi Abu Rous, and Shirish Gadgeel
The Polymerase Epsilon Gene Expression and Mutation Predictive Significance in Patients Receiving Immune Checkpoint Inhibitors (icis) for Non-small Cell Lung Cancer (NSCLS), A. Alshurafa, S. Alhushki, D. Alfaqheri, H. Abushukair, B. N. Alzghoul, and Fawzi Abu Rous
Black/African American participation in cancer clinical trials: A qualitative study of community members, patients with cancer, and survivors (Detroit, MI) using CBPR, Sylvester Antwi, Linda Kaljee, Doreen Dankerlui, Eleanor M. Walker, Harriet Larrious-Lartey, Barbara Brush, Barbara Israel, Donna Harris, Sophia Chue, Nayomi Cawthome, Cassandra Mills, Valerie Ofori Aboah, Gwendolyn Daniels, Livingstone Aduse-Poku, Chris M. Coombe, Zachary Rowe, La'Toshia Patman, Wayne Ramocan, Denise White-Perkins, and Evelyn M. Jiagge
Nuclear exporter protein exportin 1 (XPO1) as a novel therapeutic target in pancreatic neuroendocrine tumors, A. S. Azmi, M. H. Uddin, S. F. Bannoura, H. M. Khan, Maria Diab, S. Kim, E. Beal, M. Tobon, H. Chen, R. Beydoun, G. Dyson, R. M. Mohammad, Philip A. Philip, M. N. Al-Hallak, B. F. El-Rayes, and B. Pasche
RGI-2001 with CNI-Based Prophylaxis Demonstrates Better Acute Gvhd-Free Survival Following Myeloablative Allohct without Increased Relapse: Comparison of a Multi-Center Phase 2b Study with a Contemporaneous CIBMTR Cohort, Yi-Bin Chen, Shatha Farhan, Lazaros J. Lekakis, Gary J. Schiller, Jean A. Yared, Markus Y. Mapara, Amer Assal, Hannah Choe, Zachariah DeFilipp, Dana D. Lee, Hayley Lane, Linda J. Burns, Mei-Jie Zhang, Matthew Bye, Ted A. Gooley, and Ayman Saad
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced HNSCC, Byoung Chul Cho, Omid Hamid, Xinhua Zhu, Bhumsuk Keam, John M. Kaczmar, Stephen K. Williamson, Ariel E. Birnbaum, Afshin Dowlati, Grace K. Dy, Steven Jeffrey Hager, Filipa Lynce, Raymond S. McDermott, Debashis Sarker, Amy M. Weise, Timothy A. Yap, Emrullah Yilmaz, Fang Fang, Jayakumar Mani, Glenn Scott Kroog, and Kyriakos P. Papadopoulos
Fractionated docetaxel (D) and radium 223 (Ra223) in metastatic castrationresistant prostate cancer (CRPC): A modular phase I trial, Brendan Connell, Clara Hwang, Edmund Folefac, Christian Lawlor, Benjamin Koethe, and Paul Mathew
HEALTHCARE-ASSOCIATED INFECTIONS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A NATIONWIDE ANALYSIS, John Cuenca, Bernard Moscoso, Diana Cardenas, Marissa Schettino, Daniel Gonzalez-Mosquera, Pool Tobar, Luis Gonzalez-Mosquera, and Joseph Nates
Pulsed low dose rate radiation to mitigate tumor-permissive responses in pancreatic cancer-associated fibroblasts: Introducing the HOST-factor, Edna Cukierman, Janusz Franco-Barraza, Tiffany Luong, Kristopher Raghavan, Jessica K. Wong, Débora Barbosa Vendramini Costa, Ralph Francescone, Jaye C. Gardiner, Sanjay S. Reddy, Elizabeth A. Handorf, and Joshua E. Meyer
Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial, Rafal Dziadziuszko, Fabrice Barlesi, Jeong Eun Kim, Shirish M. Gadgeel, Maciej Krzakowski, Jae Ho Jeong, Gennaro Daniele, David Chen, Youyou Hu, Timothy R. Wilson, Brian P. Simmons, and David M. Thomas
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study, Enriqueta Felip, Byoung Chul Cho, Vanesa Gutiérrez, Adlinda Alip, Benjamin Besse, Shun Lu, Alexander I. Spira, Nicolas Girard, Raffaele Califano, Shirish M. Gadgeel, James Chih-Hsin Yang, Naoyuki Nogami, Koichi Azuma, Joshua C. Curtin, Jiarui Zhang, Anesh Panchal, Mariah Ennis, Seema Niphadkar Sethi, Joshua Michael Bauml, and Se-Hoon Lee
TIGIT expression increases with advancing clinical stages of resected pancreatic cancer, Madison George, Julie Clark, Kendyll Gartrelle, Georges Nassif, Kailee Hartway, Daniel Long, Daniel Salas-Escabillas, Allison Wombwell, Thais Pichardo, Hui-Ju Wen, Simone Benitz, Samuel Zwernik, Rupen Shah, Hakmin Park, Philip Philip, Gazala Khan, Howard Crawford, David Kwon, Brian Theisen, and Nina Steele
Longitudinal tissue-based evaluation of TIGIT expression in patients with pancreatic cancer: Effect of expression with advancing clinical stages and across racial groups, Madison George, Julie Clark, Kailee M. Hartway, Samuel Zwernik, Kendyll Gartrelle, Daniel Salas-Escabillas, Daniel Long, Georges Nassif, Thais Pichardo, Allison Wombwell, Hui-Ju Wen, Simone Benitz, Philip A. Philip, Gazala Khan, Rupen A. Shah, Hakmin Park, Howard C. Crawford, David S. Kwon, Brian Theisen, and Nina Steele
Factors influencing career choices and post-fellowship perspectives in adult hematology/oncology fellows: A nationwide cross-sectional study, Luis F. Gonzalez Mosquera, Nino Balanchivadze, Faria Ali, Matthew Meranda, Oscar Hinojosa Castro, and Philip Kuriakose
Abatacept with FluBu2: To Use or Not to Use, Luis F. Gonzalez-Mosquera, Klodiana Neme, Nancy Mikulandric, Izabela Mazur, Josephine Emole, Asif Alavi, Edward Peres, Muneer H. Abidi, and Shatha Farhan
The silent burden: A SEER-based analysis of potential years of life lost due to genitourinary cancers in the United States (1975-2017), Rajvi Gor, Pranav Gwalani, Dhairya Gor, Anand Shah, Rahul Kumar Thakur, and Benjamin Adam Gartrell
Pain, palliation, and opioid use patterns: A nationwide analysis of neoplasm-related pain admissions and trends (2016-2020), Rajvi Gor, Pranav Gwalani, Dhairya Gor, Anand Shah, Rahul Kumar Thakur, and Abhishek Kumar
PM2.5 and risk of lung cancer and associated mortality: An umbrella meta-analysis, Ashima Gupta, Abhishek Singh, Baris Tarimci, Alamjeet Kaur Sindhu, Pinank Bathvar, Simranjeet Bedi, Nyein Wint Yee Theik, Vedant Shah, Saarthak Malhotra, Milan Khealani, Sri Usha Jeevani Obulareddy, Geetika Kukreja, and Amaraja Kanitkar
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA), Christopher Hanyoung Lieu, Guan Yu, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Ibrahim Halil Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Arvind Dasari
195MO Tarlatamab in previously treated small cell lung cancer (SCLC): DeLLphi-300 phase I study long-term outcomes and intracranial activity, H-D. Hummel, S. Champiat, M. E. Olmedo Garcia, M. Boyer, K. He, N. Steeghs, H. Izumi, M. L. Johnson, T. Yoshida, H. Bouchaab, A. Dowlati, H. Borghaei, E. Felip, P. J. Jost, Shirish Gadgeel, X. Chen, Y. Yu, P. Martinez, A. Parkes, and L. Paz-Ares
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3, Maen A. Hussein, Gazala Khan, Sreenivasa R. Chandana, Roberto A. Pazo Cid, Igor Kiss, Javier Gallego, Teresa Macarulla, Christelle De La Fouchardiere, Thorsten Goetze, Andrew Peter Dean, Eileen M. O'Reilly, Zev A. Wainberg, Woo Jin Lee, Eric Van Cutsem, Richard Hubner, Andrew S. Paulson, Tanios S. Bekaii-Saab, Shubham Pant, Fiona Maxwell, and Davide Melisi
Standard Risk Assessment Tools Fall Short to Assess Risk in Transplant Patients, Radhika Kulkarni, Luis F. Gonzalez, Chun-Hui Lin, Courtney Rose, Josephine Emole, Asif Alavi, Edward Peres, Muneer H. Abidi, and Shatha Farhan
Leukocyte immunoglobulin-like receptor (LILRB2)-targeted JTX-8064 plus the anti- PD1 inhibitor JTX-4014 (pimivalimab) in immune-checkpoint inhibitor (ICl) pretreated patients (pts) with advanced or metastatic renal cell cancer (mRCC): Results from the multi-stage phase 1-2 INNATE trial, Primo N. Lara Jr., Stew Kroll, Jonathan Alhaj Chatzkel, Deanna Gek Koon Teoh, Vincent T. Ma, Deepak Kilari, Clara Hwang, Randy F. Sweis, Kiran Yalamanchili, Julio A. Peguero, Tianhong Li, and Mamta Parikh
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002), Xiuning Le, Alexander I. Spira, Shirish M. Gadgeel, Jonathan W. Riess, Yan Yu, Yanqiu Zhao, Ying Cheng, Oscar Juan-Vidal, Bo Gao, Kiyotaka Yoh, Martin Forster, Satoru Kitazono, Hidetoshi Hayashi, David Planchard, Yong Jiang, Nichole Baio, Marcin Kowanetz, William Leung, Jerry Y. Hsu, and Jie Wang
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%, Melissa Lynne Johnson, Edurne Arriola, Terufumi Kato, Nicolas Girard, Shirish M. Gadgeel, Jie Wang, Xia Li, Caitlin Lowery, Lee M. Krug, and Myung-Ju Ahn
Association of tumor genetics with outcomes in patients (pts) with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA- 617, Justine Panian, Nicholas Henderson, Pedro C. Barata, Mehmet Asim Bilen, Laura Graham, Elisabeth I. Heath, Daniel Herchenhorn, Clara Hwang, Deepak Kilari, Vadim S. Koshkin, Jones T. Nauseef, Alexandra Sokolova, Yousef Zakharia, Michael T. Schweizer, Tanya B. Dorff, Andrew J. Armstrong, Ajjai S. Alva, and Rana R. McKay
Patient-reported and clinical outcomes among patients with pancreatic cancer, Rayli Pichardo, Brigid Jacob, Maria Jamil, Dawood Jamil, Shahm Raslan, Courtney M. Rose, Eric Adjei Boakye, Laila Poisson, Samantha Tam, and Philip A. Philip
Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors, Sarina A. Piha-Paul, Macarena Ines De La Fuente, Fabio Iwamoto, Seema Nagpal, Amy M. Weise, Jay-Jiguang Zhu, Sunandana Chandra, Chen Chen, Yali Fu, Zandong Yang, and Katy K. Tsai
Race and decisional conflict about genetic testing in patients with advanced prostate cancer, James P. Purtell, Avery Ralston, Courtney M. Rose, Kyle McElyea, Farhan Ibrahim, Alexandra Thompson, Sunita Ghosh, and Clara Hwang
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL), M. Rizwan Rizwan-ul-Haq Khawaja, Abdul Rafeh Naqash, Reva Schneider, Aditi Shastri, Maximilian Stahl, Justin C. Moser, Nagla Fawzy Abdel Karim, Yazan Madanat, Brian A. Jonas, Eytan Stein, Shirish M. Gadgeel, James K. McCloskey, Ashwin Gollerkeri, Rachelle Perea, Yogesh Chutake, Sagar Agarwal, Patrick Henrick, Kelvin Shi, and Naval G. Daver
SWOG S2303: Randomized phase II/III trial of 2nd line nivolumab + paclitaxel + ramucirumab versus paclitaxel + ramucirumab in patients with PD-L1 CPS 1 advanced gastric and esophageal adenocarcinoma (PARAMUNE), Anwaar Saeed, Sarah Colby, Paul Eliezer Oberstein, Dan G. Duda, Rajiv Agarwal, Colmar Figueroa-Moseley, Riha Vaidya, Joseph M. Unger, Katherine A. Guthrie, Flavio G. Rocha, Maheswari Senthil, Rachael A. Safyan, Zev A. Wainberg, Syma Iqbal, E. Gabriela Chiorean, and Philip A. Philip
Diversity of patients enrolled in SWOG gastrointestinal cancers therapeutic trials, Rachael A. Safyan, Sarah Colby, Colmar Figueroa-Moseley, Katherine A. Guthrie, E. Gabriela Chiorean, and Philip A. Philip
Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9, Douglas W. Sborov, Charlotte Pawlyn, Tadao Ishida, Jeffrey S. Y. Huang, Reuben Benjamin, Shinsuke Iida, Rakesh Popat, Junya Kuroda, Matthew J. Pianko, Aravind Ramakrishnan, Steven R. Schuster, Vrushali S. Dabak, Alexander M. Lesokhin, Umberto Conte, Pooneh Soltantabar, Fangxin Hong, Erik Vandendries, and Rafael Fonseca
A Phase I/II Study of GDA-201, Cryopreserved Nicotinamide-Enhanced Allogeneic Natural Killer Cells, in Patients with Relapsed/Refractory B-Cell Lymphoma, Brian C. Shaffer, Matthew J. Frigault, Muhamad Alhaj Moustafa, Edward Peres, Stephanie B. Tsai, Stuart Levy, Yona Geffen, Roei Mazor, and Veronika Bachanova
Beyond the initial diagnosis: Epidemiological factors associated with second primary cancers among patients with head and neck squamous cell carcinoma (a SEER-based study), Anand Shah, Pranav Gwalani, Rajvi Gor, Dhairya Gor, Abiram Sivanandam, and Anupama H. Nehra
Evaluation and treatment response in patients with hormone receptor-positive, HER2 low metastatic breast cancer: A single center retrospective analysis, Muhammad A. Shahid, Radhika B. Kulkarni, Linda Albusoul, Brigid Jacob, Courtney M. Rose, Kylie Springer, and Vrushali S. Dabak
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer, Yan-Shen Shan, Chung-Pin Li, Gazala Khan, Woo Jin Lee, Hye Jin Choi, Heung-Moon Chang, Moon Hee Lee, John M. Wallmark, and Pei-Ni Chen
A phase I/II study of antroquinonol in combination with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer, Yan-Shen Shan, Chung-Pin Li, Gazala Khan, Woo Jin Lee, Hye Jin Choi, Heung-Moon Chang, Moon Hee Lee, John M. Wallmark, and Pei-Ni Chen
Ipatasertib in patients with AKT1/2/3 mutation-positive (AKTmut) tumors: TAPISTRY study, David Thomas, Gennaro Daniele, Jeong Eun Kim, Shirish M. Gadgeel, Eugene R. Ahn, Luis G. Paz-Ares, Hans Prenen, David Chen, Junhan Fang, Timothy R. Wilson, Brian Simmons, and Fabrice Barlesi
PP01.69 Atypical Lung Carcinoids with EML4-ALK Fusion and Responses to ALK Inhibitors, Sarah Waliany, Yin P. Hung, Fawzi Abu Rous, Andrew Do, Jennifer Peterson, Caitlin Meservey, Subba R. Digumarthy, Shirish M. Gadgeel, Jessica J. Lin, and Catherine B. Meador
Upstaging from cT1 to pT2 in Triple Negative and Her2 Positive Breast Cancer: an Opportunity to Identify cT1 Breast Cancer Patients for whom Neoadjuvant Chemotherapy Should be Considered, Rachel Wobig, Jessica M. Bensenhaver, Hemi Thaker, Christine Joliat, Theresa L. Schwartz, Anna V. Lehrberg, Laura K. Dalla Vecchia, Saul D. Nathanson, Laura L. Susick, Kylie Springer, Lindsay F. Petersen, and Haythem Ali
Engraftment Day Electrolytes and Hydration and the Risk of Atrial Fibrillation Early after Hematopoietic Stem Cell Transplant, Min Wu, Adnan Khan, Edward Peres, Josephine Emole, Asif Alavi, Muneer H. Abidi, Madhulata Reddy, and Shatha Farhan
The impact of SPOP gene alterations in men with metastatic prostate cancer: Results from the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) consortium, Kyra L. Yamamoto, Nicholas Henderson, Clara Hwang, Pedro C. Barata, Mehmet A. Bilen, Deepak Kilari, Laura Graham, Rohan Garje, Shoshana Rothstein, Vadim S. Koshkin, Abhishek Tripathi, Frank C. Cackowski, Jones T. Nauseef, Michael T. Schweizer, Andrew J. Armstrong, Tanya B. Dorff, Ajjai S. Alva, and Rana R. McKay
A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies, Frank Yung-Chin Tsai, Michael J. Birrer, Jason R. Brown, Sanjay Chandrasekaran, Vincent Chung, Richard C. Frank, Edward G. Garmey, Shirish M. Gadgeel, Thomas J. George, Shadia I. Jalal, Andrew S. Poklepovic, Jennifer M. Segar, Alexander I. Spira, Jue J. Zhang, and Anup Kasi
Submissions from 2023
THE ASSOCIATION BETWEEN MESOTHELIAL MEMBRANES METASTASIS AND RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN SOLID TUMORS, Hassan Abushukair, Constantine Logothetis, Fawzi Abu Rous, Anwaar Saeed, Olivia Aranha, and Moh’d Khushman5
Trend in Von Willebrand Factor Profile in Women With Von Willebrand Disease During Pregnancy and Postpartum, Linda Albusoul, Muhammad Shahid, Sowjanya Vuyyala, Zaher K. Otrock, and Philip Kuriakose
EP03.03-02 Multi-omics Analysis of Immune Determinants of STK11 in Non-Small Cell Lung Cancer, S. K. Alhushki, A. Al-Muhtaseb, H. Abushukair, and Fawzi Abu Rous
Implementing Quality Improvement to Morbidity and Mortality Conferences: Focusing on Action Plans By Closing the Loops with Timely Follow Ups, Zaid Al-Saheli and Vijaya Donthireddy
Molecular characterization and clinical outcomes of pancreatic neuroendocrine tumors (pNENs) harboring PAK4-NAMPT alterations, Ibrahim Azar, Nishant Gandhi, Misako Nagasaka, Jun Gong, Bassel Nazha, Khalil Choucair, Moh'd M. Khushman, Heloisa P. Soares, Wafik S. El-Deiry, Philip A. Philip, Emil Lou, Alex P. Farrell, Jeffrey Swensen, Matthew J. Oberley, Jim Abraham, Chadi Nabhan, Sanjay Goel, Wolfgang M. Korn, and Anthony F. Shields
P-76 Genomic and transcriptomic characterization of pancreatic neuroendocrine tumors reveals novel therapeutic candidates, A. Azmi, Z. Mahdi, S. Bannoura, M. Al-Hallak, M. Uddin, H. Khan, I. Muqbil, R. Mohammad, H. Chen, Philip A. Philip, and B. El-Rayes
A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations, J. Thaddeus Beck, Meredith McKean, Shirish M. Gadgeel, Daniel W. Bowles, Rizwan Haq, Rona Yaeger, Matthew H. Taylor, Arnab K. Maity, Stefanie Drescher, Colleen Oliver, Ann M. Huelskamp, Gang Feng, and Keren Sturtz
Single-cell epigenomic analysis reveals an important role of the receptor kinase Ror2 in the erosion of cellular identity during pancreatic carcinogenesis, Simone Benitz, Malak Nasser, Alexander Steep, Ian Loveless, Hui-Ju Wen, Daniel Long, Erick T. Davis, Donald Rempinski, Michaela Louw, Jacee Moore, Nina Steele, Ujjwal Mahajan, Ivonne Regel, Filip Bednar, and Howard Crawford
First Report of Asymptomatic Solitary High-Grade B-Cell Lymphoma NOS: An Enigmatic Entity, Seif Bugazia, Nakul Gandhi, Niluka Weerakoon, and Geetika Kukreja
Efficacy of the Addition of RGI-2001 to Tacrolimus and Methotrexate for Acute Gvhd Prevention in Myeloablative HSCT Using HLA-Matched Donors, Yi-Bin Chen, Shatha Farhan, Lazaros J. Lekakis, Gary J. Schiller, Jean Adel Yared, Amer Assal, Dana D. Lee, Hayley Lane, Ted A. Gooley, Zachariah DeFilipp, and Ayman Saad
Incidence of Positive Sentinel Lymph Node in cN0(f) Breast Cancer Patients After Neoadjuvant Chemotherapy: Opportunity to Defer Intraoperative Frozen Section Analysis, Fallon Dimaano, Theresa Schwartz, Laura L. Susick, Elizabeth King MD, Christine Joliat, Anna Lehrberg, Lindsay Petersen, and Jessica Bensenhaver
EP10.01-03 A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC, A. Drilon, M. M. Awad, D. R. Camidge, P. M. Forde, M. Alexander, Shirish M. Gadgeel, L. C. Villaruz, J. Perez, T. Navas, C. Daly, S. Patel, S. Li, M. Laughlin, I. Lowy, H. Magnan, and P. Rietschel
Expression of Irf3 and Irf7 in tumour cells drives pancreatic cancer development and progression, Lisa Fahr, Simone Benitz, Tobias Straub, Jurik Mutter, Hannah Lisiecki, Ujjwal M. Mahajan, Georg Beyer, Katja Steiger, Andrea Terrasi, Gunnar Schotta, Axel Imhof, Kirsten Lauber, Jörg Kleeff, Christoph W. Michalski, Julia Mayerle, and Ivonne Regel
A Single Institution Randomized Clinical Trial Evaluating Ciprofloxacin Versus Levofloxacin As Antibacterial Prophylaxis for Patients Receiving Hematopoietic Stem Cell Transplantation, Shatha Farhan, Peter Xie, Klodiana Neme, Angela German, Nancy Mikulandric, Josena K. Stephen, Mary A. Trapp, Elizabeth A. Henne, Sarah Szymanski, Scott R. Rohrer, Danielle L. Pelland, Nada Zagar, Izabela Z. Mazur, Nada Rida, Kunj Patel, Min Wu, Neda Kortam, Aseel Yaseen, Aroob Sweidan, Josephine Emole, Edward Peres, Muneer H. Abidi, and Mayur Ramesh
MA06.04 KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC, Shirish M. Gadgeel, P. A. Jänne, A. I. Spira, S.-H. I. Ou, R. S. Heist, J. M. Pacheco, M. L. Johnson, J. K. Sabari, K. Leventakos, J. A. Mason, K. Velastegui, X. Yan, R. Chao, and G. J. Riely
1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A, Shirish M. Gadgeel, T. S. K Mok, S. Peters, E. Nadal, J-Y Han, J. A. Alatorre Alexander, N. Leighl, V. Sriuranpong, M. Pérol, G. D. Castro, F. de Marinis, D. S. W Tan, S. Paul, Z. J. Assaf, M. MacLennan, T. O. Lohmann, M. Slade, M. S. Mathisen, V. Bhagawati-Prasad, and R. Dziadziuszko
OA14.05 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%, Shirish M. Gadgeel, D. Rodríguez-Abreu, B. Halmos, M. C. Garassino, T. Kurata, Y. Cheng, E. Jensen, M. Shamoun, K. Rajagopalan, and L. Paz-Ares
EP12.01-64 Metastatic Non-Small Cell Lung Cancer With EGFR Mutations: Treatment Pattern and Outcomes From a Systematic Literature Review, Shirish M. Gadgeel, E. Wang, S. Phani, C. Wu, M. Salas, J. Meng, F. Diamand, S. Esker, and D. W-T Lim
1388P Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC), Shirish M. Gadgeel, Q. Zhang, H. Lin, O. Fajardo, H. Trinh, S. Arndorfer, S. Kong, A. Rahman, S. Li, V. R. Archer, and J. F. Gainor
Characteristics and outcomes of patients with small cell lung cancer (SCLC) detected with CT screening at a single health system, Manasi M. Godbole, Pin Li, Kashmira Wani, Matthew Meranda, Michael J. Simoff, and Shirish M. Gadgeel
Lowering the bar for consideration of neoadjuvant chemotherapy in early-stage HER2- positive breast cancers, Manasi M. Godbole, Matthew Meranda, Kathren Shango, and Vrushali S. Dabak
P2.09-39 Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers, Radhika Gutta, Fawzi Abu Rous, E. Teslow, E. Jaeger, Shirish M. Gadgeel, and Bindu Potugari
43001 Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis, Omid Hamid, Amy Weise, Karl D. Lewis, Tae M. Kim, Meredith McKean, Nehal J. Lakhani, John Kaczmar, Kyriakos P. Papapoulos, Shuquan Chen, Jayakumar Mani, and Giuseppe Gullo
XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers, Erika Hamilton, Alexander Spira, Sylvia Adams, Nour Abuhadra, Antonio Giordano, Ritesh Parajuli, Hyo Han, Amy Weise, Aubri Marchesani, Kate Josephs, Arvind Chaudhry, and Kevin Kalinsky
XMT-1660: A Phase 1b trial of a B7-H4 targeting antibody drug conjugate (ADC) in endometrial, ovarian, and breast cancers (1250), Erika Hamilton, Alexander Spira, Sylvia Adams, Nour Abuhadra, Antonio Giordano, Ritesh Parajuli, Hyo Han, Amy Weise, Aubri Marchesani, Kate Josephs, Arvind Chaudhry, and Kevin Kalinsky
Efficacy and Safety of Eptacog Beta (Recombinant Activated FVII) in Patients with Hemophilia A or B with Inhibitors According to Time to Initial Infusion: A Post-Hoc Analysis from PERSEPT-1, C. Hermans, M. Escobar, Y. Abajas, S. Acharya, M. Alvarez-Román, G. Batsuli, Y. Dargaud, M. Janbain, Philip Kuriakose, J. Mahlangu, M. Mancuso, W. Miesbach, S. Yuan, I. Mitchell, and M. Carcao
Post-Transfusion Purpura: A Literature Review, Oscar Hinojosa, Omar Ammari, Linda Albusoul, Philip Kuriakose, and Zaher K. Otrock
Infusion Reactions with Alternative Therapies during the National Shortage of Iron Dextran, Brigid Jacob, Maria Jamil, Shahm Raslan, Zeinab Nasser, Kylie Springer, Angela Michael German, and Philip Kuriakose
Efficacy of Direct Oral Anticoagulants Vs Warfarin Vs Low Molecular Weight Heparin in the Treatment of Acute Splanchnic Vein Thrombosis in Patients with Underlying Myeloproliferative Disorder, Maria Jamil, Zeinab Nasser, Brigid Jacob, Ruchi Mangal, and Vijaya Donthireddy
8MO Adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency, P. A. Jänne, A. Spira, G. J. Riely, Shirish M. Gadgeel, R. Heist, S. H. I. Ou, M. L. Johnson, J. Sabari, K. Velastegui, J. G. Christensen, W. Yang, K. Anderes, R. Chao, and C. Paweletz
81TiP NVL-655, a selective anaplastic lymphoma kinase (ALK) inhibitor, in patients with advanced ALK-positive solid tumors: The phase I/II ALKOVE-1 study, M. L. Johnson, S. H. I. Ou, E. Felip, C. Baik, B. Besse, J. Mazieres, D. R. Camidge, Shirish M. Gadgeel, A. Drilon, Y. Y. Elamin, G. Liu, J. E. Reuss, T. Kehrig, H. E. Pelish, V. Zhu, and J. J. Lin
A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic adenocarcinoma, Mandana Kamgar, Husain Y. Khan, Amro Aboukameel, Sahar Bannoura, Brian Y. Chung, Aniko Szabo, Yiwei Li, Mohammed N. Al Hallak, Philip A. Philip, Ben George, Kathleen K. Christians, Douglas B. Evans, Susan Tsai, Beth Erickson, Sanjeev Luther, Asfar S. Azmi, and William A. Hall
Epidemiology and Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A US Population-Based Study, Ujjwal Karki, Pravash Budhathoki, Anish Shah, Bipin Ghimire, Shyam K. Poudel, and Mohammad Muhsin Muhsin Chisti
Real World Analysis of G6PD Testing Prior to the Use of Rasburicase in Hematologic Malignancies; A Single Center Experience, Radhika Kulkarni, Oscar Hinojosa, and Vijayalakshmi Donthireddy
A perilous and complicated situation in hospitals: Vitamin D deficiency in multiple myeloma patients-A nationwide cross-sectional study, Manisha R. Lakhanpal, Nikhila Chelikam, Divesh Manjani, Simmy Lahori, Sai A. Akella, Prashanth G. Shivashankar, Shlok V. Shah, Abdirazak Ali, Varneet Toor, Aryak Singh, Rahul Gujarathi, Lokesh Manjani, Urvish Patel, Avinash Adiga, and Geetika Kukreja
Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers), Michael S. Lee, Aparna R. Parikh, David R. Spigel, Farshid Dayyani, Alexander I. Spira, Chloe E. Atreya, Susanna V. Ulahannan, John H. Strickler, Marwan Fakih, Patrick Grierson, Eric Christenson, Darryl Outlaw, Gazala Khan, Scott Kopetz, Andrea J. Bullock, Zhengrong Li, Xiaoying Chen, Hina Patel, Saswati Hazra, and E. Gabriela Chiorean
NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US), Christopher H. Lieu, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim H. Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Arvind Dasari
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis, Inderjit Mehmi, Karl D. Lewis, Amy M. Weise, Meredith McKean, Kyriakos P. Papadopoulos, John Crown, Sajeve S. Thomas, Eugenia Girda, John M. Kaczmar, Kevin B. Kim, Nehal J. Lakhani, Melinda L. Yushak, Omid Hamid, Jayakumar Mani, Fang Fang, Israel Lowy, and Giuseppe Gullo
EFFICACY AND SAFETY OF EPTACOG BETA (RECOMBINANT HUMAN FVIIA) ACCORDING TO AGE IN PERSONS WITH HAEMOPHILIA A/B WITH INHIBITORS UNDERGOING SURGICAL PROCEDURES, W. Miesbach, M. Escobar, L. Boggio, S. Bonanad, G. Castaman, Y. Darguard, A. Giermasz, C. Hermans, Philip Kuriakose, D. Quon, M. Reding, D. Q. Tran, J. Windyga, D. Bonzo, C. Macie, and J. Mahlangu
LUMINOS-102: Lerapolturev with and without α-PD- 1 in unresectable α-PD- 1 refractory melanoma, Justin Moser, Ding Wang, C. L. Cowey, Evan Pisick, Douglas B. Johnson, Joanna Kolodney, Meghan J. Mooradian, Andrew L. Pecora, Andrew S. Poklepovic, Alan Tan, Sajeve S. Thomas, Daniel Corum, Shannon R. Morris, Hannah Kittinger, Jessica Sorrentino, William G. Nichols, and Yana G. Najjar
Closing the Gap on Racial Disparities in Pancreas Cancer -the Impact of a Multidisciplinary Clinic for Surgical Patients with Pancreatic Adenocarcinoma (PDAC) in an Integrated, Tertiary Healthcare System, Georges Nassif, Meng-Hua Tao, Kendyll J. Gartrelle, Julie Clark, Kyra Langley, Farzan Siddiqui, Parag J. Parikh, Gazala Khan, Philip A. Philip, Rupen Shah, Christopher Steffes, and David Kwon
Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT), Nitin Ohri, Shruti Jolly, Benjamin T. Cooper, Rafi Kabarriti, William R. Bodner, Jonathan Klein, Chandan Guha, Shankar Viswanathan, Elaine Shum, Joshua K. Sabari, Haiying Cheng, Rasim A. Gucalp, Enrico Castellucci, Angel Qin, Shirish M. Gadgeel, and Balazs Halmos
Randomized, phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922, Michael J. Overman, Katherine A. Guthrie, Mohamed E. Salem, Katrina S. Pedersen, Aparna Kalyan, Sarah Colby, Marwan Fakih, Sepideh Gholami, Philip J. Gold, E. Gabriela Chiorean, Howard S. Hochster, and Philip A. Philip
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies, Krish Patel, Sarah Rothman, Poulomee A. Das, Stephanie Yee, Indu Ramachandran, Iphigenia Koumenis, Terry A. Cook, Ying Yuan, Nikolaus S. Trede, and Ahmad H. Mattour
Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study, M. R. Patel, T. Doi, T. Koyama, G. S. Falchook, C. F. Friedman, S. A. Piha-Paul, M. Gutierrez, M. M. Awad, Abdelwahab H. Mattour, T. Satoh, N. Okamoto, J. Singh, N. Yoshizuka, M. Qian, X .. Qian, B. P. Tran, O. Dosunmu, P. Lu, and M. L. Johnson
Factors Associated with in-Hospital Mortality in Patients with Burkitt Lymphoma - Analysis of the National Inpatient Sample (NIS), Rayli Pichardo, Aula Ramo, Yazan Abu Omar, and Vrushali S. Dabak
Prognostic Factors in Hospitalized Patients with HIV-Associated Burkitt's Lymphoma - Real World Data Analysis, Rayli Pichardo, Aula Ramo, Yazan Abu Omar, and Vrushali S. Dabak
A phase I study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor INCB099280 in select advanced solid tumors, H. Prenen, T. Lesimple, M. Robert, J-P. Machiels, B. R. Delafontaine, P. Tomasini, T. Meniawy, N. Kotecki, E. Van Cutsem, S. A. Piha-Paul, M. T. Schweizer, Shirish Gadgeel, S. Kondo, K. Ouali, Y. Kuboki, J. Daniel, V. Ebiana, J. Howe, S. Spitz, and A. Italiano
P2.06-08 Phase I/II Study of Rucaparib and Pembrolizumab Maintenance in Stage IV NSCLC after Carboplatin, Pemetrexed, Pembrolizumab, A. Qin, D. Morgensztern, S. Waqar, D. Owen, Shirish M. Gadgeel, B. Schneider, G. Kalemkerian, J. Rice, and N. Ramnath
A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613, Kanwal P. S Raghav, Katherine A. Guthrie, Scott Kopetz, Benjamin R. Tan, Crystal S. Denlinger, Marwan Fakih, Michael J. Overman, Arvind Dasari, Larry R. Corum, Lee G. Hicks, Mital Patel, Benjamin T. Esparaz, Syed Mohammad A. Kazmi, Nitya Alluri, Sarah Colby, Sepideh Gholami, Philip J. Gold, E. Gabriela Chiorean, Howard S. Hochster, and Philip A. Philip
ATHN 11: Observational Study of Long-Term Outcomes of Liver Transplantation, Margaret V. Ragni, Jessica Callis, Nabil Daoud, Brian Hu, Matthew Manuel, Jarren Santos, Jonathan Schwartz, Kenneth D. Friedman, Peter Kouides, Philip Kuriakose, Andrew D. Leavitt, Ming Y. Lim, Nicoletta Machin, Michael Recht, and Tammuella Chrisentery-Singleton
APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation-ECOG-ACRIN EA2192, Kim A. Reiss, Sung C. Hong, Anup Kasi, Eileen M. O'Reilly, Shishir K. Maithel, Xin Yao, Stanley R. Hamilton, Ben Boursi, Michael J. Pishvaian, Samuel J. Klempner, Susan M. Domchek, Paul J. Catalano, E. Gabriel Chiorean, Philip A. Philip, and Peter J. O'Dwyer
